1[1]Yarker Y, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability[J]. Drug Aging, 1995, 6:243-62
2[2]Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients[J]. Spinal Cord, 1996, 34:284-287
3[3]Buyse G, Waldeck K, Verpoorten C, et al. Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism[J]. J Urol, 1998, 160: 892-6
4[4]Buyse G,Verpoorten C,Vereecken R,et al. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction[J]. J Urol, 1998, 160: 1084-7
5[5]Amark P, Bussman G, Eksborg S. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children[J]. Eur Urol, 1998, 34: 148-53
6[6]Goldenberg MM. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder[J]. Clin Ther, 1999, 21: 634-42
7[7]Anderson RU, Mobley D, Blank B, et al. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence[J]. J Urol, 1999, 161: 1809-12
8[8]Drutz H, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder[J]. Int Urogynecol J Pelvic Floor Dysfunct, 1999, 10: 283-9
9[9]Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder[J]. Ann Pharmacother, 1999, 33(10): 1073-82
10[10]Abrams P, Freeman R, Anderstrom C, et al. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder[J]. Br J Urol, 1998, 81: 801-10
7Sellers DJ, Mckay N. Developments in the pharmacotherapy of the overactive bladder. Cyrr Opin Urol, 2007, 17(4):223-230.
8Hashim H, Abrams P. Overactive bladder: an update. Curr Opin Urol, 2007, 17(4):231-236.
9Chapple CR, Van Kerrebroeck PE, Junem ann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. B Ju Int, 2008, 102(2):1128-1132.
